Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.39 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | METAP2 | P50579 | 1/20 | 0.38 |
| ▸ | CTSA | P10619 | 1/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL746136 | 0.67 | SIRT6 (0.49) | CYP11B1CYP11B2ALDH1A1PIK3CAPIK3CG | |
| SCHEMBL5412367 | 0.64 | TSPO (0.80) | TSPO | |
| SCHEMBL3498715 | 0.63 | MMP2 (0.59) | CYP11B1CYP11B2ALDH1A1PIK3CAPIK3CG | |
| SCHEMBL3499177 | 0.62 | MKNK1 (0.55) | CYP11B1CYP11B2PIK3CAPIK3CGMKNK1 | |
| SCHEMBL4540688 | 0.62 | NAPRT (0.57) | LMNA | |
| SCHEMBL21159736 | 0.61 | NTSR1 (0.45) | CYP11B1CYP11B2NTSR1METAP2MKNK1 | |
| SCHEMBL19964502 | 0.61 | CHEK1 (0.57) | CYP11B1CYP11B2MAPK1LMNAPIK3CA | |
| SCHEMBL9431623 | 0.61 | CYP11B2 (0.62) | CYP11B1CYP11B2ALDH1A1PIK3CAPIK3CG | |
| SCHEMBL768881 | 0.61 | MAPK14 (0.58) | CYP11B1CYP11B2ALDH1A1 | |
| SCHEMBL12231011 | 0.60 | CYP11B1 (0.59) | CYP11B1CYP11B2ALDH1A1MKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191447-A1 | Novel heterocyclic compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1719761-A1 | NOVEL HETEROCYCLIC COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191447-A1 | Novel heterocyclic compound | OPRD1, GRIN3A, GRM3 | TSPO 166/4885CYP11B1 159/4885CYP11B2 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.